Zucapsaicin

Zucapsaicin
Clinical data
Trade names	Civanex
Other names	Civamide; (Z)-Capsaicin; cis-Capsaicin
Routes of; administration	Topical
ATC code	M02AB02 (WHO) ;
Identifiers
	IUPAC name (Z)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide;
CAS Number	25775-90-0;
PubChem CID	1548942;
ChemSpider	1265956;
UNII	15OX67P384;
ECHA InfoCard	100.164.527
Chemical and physical data
Formula	C18H27NO3
Molar mass	305.418 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1ccc(cc1OC)CNC(CCCC\C=C/C(C)C)=O;
	InChI InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6-; Key:YKPUWZUDDOIDPM-VURMDHGXSA-N;

Zucapsaicin (Civanex) is a medication used to treat osteoarthritis of the knee and other neuropathic pain. It is applied three times daily for a maximum of three months. Zucapsaicin is a member of phenols and a member of methoxybenzenes. It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1 that reduces pain, and improves articular functions. It is the cis-isomer of capsaicin. Civamide, manufactured by Winston Pharmaceuticals, is produced in formulations for oral, nasal, and topical use (patch and cream).

Zucapsaicin has been tested for treatment of a variety of conditions associated with ongoing nerve pain. This includes herpes simplex infections; cluster headaches and migraine; and knee osteoarthritis. It was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. It has a melting point of 71.5–74.5 °C.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.